financetom
Business
financetom
/
Business
/
Logistics firm Kuehne+Nagel to profit from complexities around global trade war
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Logistics firm Kuehne+Nagel to profit from complexities around global trade war
Mar 25, 2025 5:35 AM

By Anastasiia Kozlova

(Reuters) - Swiss logistics group Kuehne und Nagel on Tuesday said it has been capitalizing on increasingly complex global trade issues - from U.S. President Donald Trump's tariffs to the Red Sea crisis - by charging customers more for value-added services.

Since the Covid-19 pandemic, shipping and logistics firms have had to navigate several supply chain crises from backed-up sea ports in the United States and China to worker strikes and Houthi attacks on vessels in the Suez Canal.

More recently, supply chains have been rocked by the threat and implementation of Trump's tariffs on U.S. imports, and subsequent retaliatory levies imposed by the country's trade partners.There is huge customer demand for consultancy services in navigating through difficult times, CEO Stefan Paul said in a call on the company's capital markets day.Trump's tariffs, aimed at protecting domestic industries and reducing trade deficits, have had significant impact on logistics companies. "The inflationary impact of tariffs could likely hurt demand," Parash Jain, Global Head of Transport & Logistics research at HSBC, said, adding that the complexity will continue to increase with the several layers of tariffs across countries and types of cargoes. However, for logistics services providers, the added complexity has created an opportunity to expand advisory and customs services beyond traditional transportation brokering, he added. Kuehne und Nagel said last week it plans to open a new site at Texas-Mexico border to meet growing demand for customs support between the United States and Mexico.The COVID-19 pandemic caused global supply chain disruptions, leading to a surge in demand for logistics services, boosting K+N earnings in 2021 and 2022.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Innoviz Technologies Stock Is Surging Tuesday: What's Driving The Action?
Innoviz Technologies Stock Is Surging Tuesday: What's Driving The Action?
Jan 7, 2025
Innoviz Technologies Ltd ( INVZ ) shares are surging Tuesday after the company announced plans to showcase its perception software at CES 2025, demonstrating how it runs on Nvidia Corp’s Drive Orin platform. What To Know: Innoviz ( INVZ ) announced Tuesday morning that it will showcase its latest technological advancements at CES 2025. The lidar sensor and perception software...
GFL Environmental Sells Environmental Services Business for $8 Billion Enterprise Value
GFL Environmental Sells Environmental Services Business for $8 Billion Enterprise Value
Jan 7, 2025
10:21 AM EST, 01/07/2025 (MT Newswires) -- GFL Environmental ( GFL ) on Tuesday said it is selling its environmental services business for an enterprise value of $8 billion to Apollo Funds and BC Partners. GFL will retain a 44% stake in the business while Apollo Funds and BC Funds will each hold a 28% stake. The transaction is expected...
Main Street Capital Exits Pearl Meyer with $53.7 Million Realized Gain
Main Street Capital Exits Pearl Meyer with $53.7 Million Realized Gain
Jan 7, 2025
10:18 AM EST, 01/07/2025 (MT Newswires) -- Main Street Capital ( MAIN ) said Tuesday it exited debt and equity investments in Pearl Meyer & Partners following a majority recapitalization of the company by a new financial sponsor. The exit realized a gain of $53.7 million for the investment firm, according to Main Street. The firm said it received $31.6...
Recursion Pharmaceuticals Gets Regulatory Approvals for 2 Drug Trials
Recursion Pharmaceuticals Gets Regulatory Approvals for 2 Drug Trials
Jan 7, 2025
10:22 AM EST, 01/07/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) received regulatory approvals for two drug trials. The UK Medicines and Healthcare Products Regulatory Agency approved a phase 1 trial of REC-3565, a MALT1 inhibitor targeting B-cell cancers, the company said Tuesday in a statement. The US Food and Drug Administration cleared a phase 1/2 trial of LSD1...
Copyright 2023-2026 - www.financetom.com All Rights Reserved